Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis
Aethlon Medical (AEMD) and North Immunology, a private biotech firm, plan to merge in an all-stock deal. The combined company, trading as NRTX, will focus on developing NOR-101, a bispecific antibody for atopic dermatitis. A $180M private placement will fund operations into 2028. Phase 1a trials are set to start in Q1 2027, with interim data expected by mid-2027 and Phase 1b/2b data in 2028. The transaction is expected to close in Q1 2027, subject to shareholder and regulatory approvals.
How this was made
The 30-second read
Why it matters
The merger creates a larger biotech with a funded pipeline, introducing a new Nasdaq ticker (NRTX) and offering AEMD shareholders exposure to early‑stage immunology assets.
Market read
The transaction is a material M&A event in the biotech space, introducing a new publicly traded entity and significant financing.
What to watch
Potential delays in regulatory approval for the new ticker and integration risks.
Background
Aethlon Medical (AEMD) is merging with privately held North Immunology, raising $180M to fund development of the IL‑13 x IL‑18 bispecific antibody NOR‑101 for atopic dermatitis.
Ticker impact
Aethlon Medical announced a definitive all‑stock merger with North Immunology, creating a new public company.
Short‑term pressure on AEMD shares; long‑term upside if NOR‑101 progresses.
Deal size $180M and new ticker NRTX indicate material change; market will reprice exposure to the combined entity.
Market effects
Biotech sector may see increased interest in bispecific antibody platforms.
US biotech investors gain a new listed vehicle; no immediate regional effect.
Adds a new Nasdaq‑listed biotech, modest global impact.
Counterpoint
Deal could overvalue North Immunology's early‑stage assets; dilution risk for AEMD shareholders.
Key entities
- CompanyAethlon Medical, Inc.
Public biotech (Nasdaq: AEMD) merging with North Immunology.
- CompanyNorth Immunology, Inc.
Private biotech developing bispecific antibody NOR‑101.
